ReviewTranslational oncology2019
PTEN Hamartoma Tumor Syndrome and Immune Dysregulation.
Review in Translational oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- Genomic diversity in functionally relevant genes modifies neurodevelopmental versus neoplastic risks in individuals with germline PTEN variants.NPJ genomic medicine · 2025Article
- [Thyroid cancer in a child with Cowden syndrome].Problemy endokrinologii · 2024Article
- Myeloid PTEN loss affects the therapeutic response by promoting stress granule assembly and impairing phagocytosis by macrophages in breast cancer.Cell death discovery · 2024Article
- Interleukin-1β: Friend or foe for gastrointestinal cancers.World journal of gastrointestinal oncology · 2024Article
- Insights into Clinical Disorders in Cowden Syndrome: A Comprehensive Review.Medicina (Kaunas, Lithuania) · 2024Review
- PTEN hamartoma tumour syndrome: case report based on data from the Iranian hereditary colorectal cancer registry and literature review.Diagnostic pathology · 2023Review
- Hereditary cancer syndromes.World journal of clinical oncology · 2023Review
- PTEN in Immunity.Current topics in microbiology and immunology · 2022Article
- Polygenic autoimmune disease risk alleles impacting B cell tolerance act in concert across shared molecular networks in mouse and in humans.Frontiers in immunology · 2022Review
- Lymphadenopathy at the crossroad between immunodeficiency and autoinflammation: An intriguing challenge.Clinical and experimental immunology · 2021Review
- Treatment of Immune Dysregulation Due to a PTEN Variant with Sirolimus.Journal of clinical immunology · 2021Article
- Selected Topics in the Pathology of the Thyroid and Parathyroid Glands in Children and Adolescents.Head and neck pathology · 2021Review
- Interplay Between Class II HLA Genotypes and the Microbiome and Immune Phenotypes in Individuals With PTEN Hamartoma Tumor Syndrome.JCO precision oncology · 2021Article
- Two Monogenetic Disorders, Activated PI3-Kinase-δ Syndrome 2 and Smith-Magenis Syndrome, in One Patient: Case Report and a Literature Review of Neurodevelopmental Impact in Primary Immunodeficiencies Associated With Disturbed PI3K Signaling.Frontiers in pediatrics · 2021Article
- Disorders Related to PI3Kδ Hyperactivation: Characterizing the Clinical and Immunological Features of Activated PI3-Kinase Delta Syndromes.Frontiers in pediatrics · 2021Review
- Germline PTEN mutations are associated with a skewed peripheral immune repertoire in humans and mice.Human molecular genetics · 2020Article
- PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy.International journal of molecular sciences · 2020Review
- Transcriptomic Analysis of Cellular Pathways in Healing Flexor Tendons of Plasminogen Activator Inhibitor 1 (PAI-1/Serpine1) Null Mice.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2020Article
- Heterogeneity of Liver Disease in Common Variable Immunodeficiency Disorders.Frontiers in immunology · 2020Review
- Control of T lymphocyte fate decisions by PI3K signaling.F1000Research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carriers of a pathogenic germline mutations in the PTEN gene, a well-known tumor suppressor gene, are at increased risk of multiple benign and malignant tumors, e.g. breast, thyroid, endometrial and colon cancer. This is called PTEN Hamartomous Tumor Syndrome (PHTS). PHTS patients may also have an increased risk of immunological dysregulation, such as autoimmunity and immune deficiencies. The effects of PTEN on the immune system have been studied in murine knockout models demonstrating that loss of PTEN function leads to dysregulation of the immune response. This results in susceptibility to autoimmunity, impaired B cell class switching with subsequent hypogammaglobulinemia. Additionally, a decreased ability of dendritic cells to prime CD8
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.